Drug Index

Emicizumab

 
print

Mechanism :

Emicizumab-kxwh, a humanized monoclonal modified immunoglobulin G4 (IgG4) antibody with a bispecific factor IXa- and factor X-directed antibody, bridges activated factor IX and factor X to restore the function of missing activated factor VIII that is needed for effective hemostasis.


Indication :

• Hemophilia A prophylaxis


Contraindications :

No contraindications.


Dosing :

Subcutaneous: Initial: 3 mg/kg once weekly for 4 weeks. Maintenance: 1.5 mg/kg once weekly or 3 mg/kg once every 2 weeks or 6 mg/kg once every 4 weeks.


Adverse Effect :

Headache, antibody development, injection site reaction, diarrhea, arthralgia, myalgia, fever.


Interaction :

Anti-inhibitor Coagulant Complex (Human): Emicizumab-kxwh may enhance the thrombogenic effect of Anti-inhibitor Coagulant Complex (Human).
Belimumab: Monoclonal Antibodies may enhance the adverse/toxic effect of Belimumab.


07/17/2019 20:57:06 Emicizumab
ask a doctor
Ask a Doctor
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0